Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMoving up on Mounjaro is not automatic, and the decision belongs to your prescriber — not a calendar. Tirzepatide's licensed schedule starts at 2.5 mg and steps through 5, 7.5, 10, 12.5 and 15 mg, with roughly four weeks at each level, but whether a particular increase is right for you depends on how your body is responding, what side effects you're experiencing and whether the current dose is still doing useful clinical work. These are prescription-only medicines that require a clinical assessment before any change; tirzepatide's mechanism and licensed uses are explained in full if you want the background first.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The single biggest misconception about Mounjaro dose escalation is that it runs on a strict monthly clock. People often expect that after four weeks at 2.5 mg, 5 mg follows automatically, and then 7.5 mg, and so on. That is not how the licensed schedule is intended to work.
The four-week intervals in the SmPC are a minimum, not a trigger. They exist because four weeks gives your system enough time to reach a new steady state and for your prescriber to judge whether the current dose is tolerable and therapeutically active. If you are still managing notable nausea, vomiting or other GI symptoms at week four, moving up is likely to intensify those effects rather than reduce them. The NHS patient information on tirzepatide is clear that the starting dose is a tolerability step, its job is to let your body adjust before the clinically active doses begin.
So if you are asking whether you should move up, the first question is not "has it been four weeks?", it is "how well am I tolerating what I am on, and is this dose still actively supporting weight loss?" Those are different questions, and our dedicated guide on when to move up on Mounjaro walks through the signals a prescriber considers before approving an increase. A real clinician reviews that picture; the decision is not one a checklist can make for you.
At a dose-review, a prescriber is weighing several things in combination. Side-effect burden is the most immediate: persistent nausea, repeated vomiting or significant GI distress at the current dose is a strong signal that the body needs more time, not a higher dose. Tolerability is a prerequisite, not a nice-to-have.
Beyond tolerability, the clinical question is whether the current dose is still generating a meaningful response. Early in treatment, even lower doses drive noticeable appetite reduction and early weight change. Over time, if the response plateaus before the highest tolerated dose, a step up may be appropriate. If weight loss is continuing steadily and side effects are well-managed, a prescriber may choose to stay at the current dose, there is no clinical imperative to reach 15 mg if a lower dose is working well.
Transfer patients and those requesting a dose increase at a regulated online pharmacy like nume are asked to provide evidence of their current treatment and how they are getting on with it. That is not bureaucracy; it protects you. Dispensing a higher strength without that review is not responsible practice. If you are thinking about whether Mounjaro is the right medicine at all, the broader question of whether to start Mounjaro has its own dedicated resource.
Every repeat order through nume (including a step to a new strength) goes through a fresh clinical review by a GPhC-registered Independent Prescriber. A named clinician reads your case; no automated system approves a higher dose. If you are requesting 5 mg after a period at 2.5 mg, or 10 mg after 7.5 mg, you will be asked how the current dose has been going: side effects, tolerability, how your body has responded.
If the prescriber is satisfied, the new strength is approved and dispatched the same day for orders placed before midday on a working day. The pen arrives with DPD the next working day in plain, unbranded packaging, nothing on the outside to suggest what's inside. That is the process for every dose change, every time.
For context on what treatment through a private pharmacy typically involves in terms of cost, our Mounjaro price comparison guide explains what to look for beyond the headline number, including what happens when a dose change brings a change in price.
If you are unsure whether the step you are considering is appropriate, our guide on whether Mounjaro is right for you is a good place to work through the question before speaking to a prescriber. Our clinical team oversees all prescribing at nume and is available to answer questions through aftercare seven days a week.
These are prescription-only medicines and the right dose for you is a clinical judgement. If you haven't yet started treatment and want to understand what the process involves, our dedicated page on whether to start Mounjaro walks through what to consider, and you can also start a free consultation and a prescriber will review your case the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.